A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants
Status:
Completed
Trial end date:
2017-01-04
Target enrollment:
Participant gender:
Summary
The study will aim to evaluate the following:
- Whether there are any differences in the way the body handles LY2963016 U-200 and
LY2963016 U-100.
- How well-tolerated LY2963016 U-200 is compared with LY2963016 U-100.
- How LY2963016 U-200 affects the level of blood sugar in the body compared with LY2963016
U-100.
The study will last up to 17 weeks for each participant, including initial screening and
follow up.